Euro area ig corporate bonds: some leeway for tighter speards still left

The rally in euro area (EA) corporate bonds has continued unabated for three months. Year-to-date spreads have tightened by more than 40 bps and corporates have yielded a total return of more than 3%. The lack of ECB purchases and the strong issuance activity did not prevent the strong performance as private sector demand for this asset class was very strong.

Highlights:

  • The rally in euro area (EA) corporate bonds has continued unabated for three months. Year-to-date spreads have tightened by more than 40 bps and corporates have yielded a total return of more than 3%.
  • The lack of ECB purchases and the strong issuance activity did not prevent the strong
    performance as private sector demand for this asset class was very strong.
  • The current environment is quite benign as the macroeconomic data flow is expected to stabilize and the even more accommodative stance by the ECB will keep benchmark yields on a low level.
  • However, the air is getting thinner as corporate yields are not far from the historical lows and spreads have reversed the Q4 2018 widening completely. Still, we continue to recommend overweighting EA corporate bonds to not miss the final stage of the rally.

Download the full publication below

EURO AREA IG CORPORATE BONDS: SOME LEEWAY FOR TIGHTER SPREADS STILL LEFT

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.